Cover Image
Market Research Report

Global Vaccine Market: Focus on Product Type (Next-Generation Vaccine), Route of Administration, Disease Type, 22 Countries Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2028

Published by BIS Research Inc. Product code 752400
Published Content info 278 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Vaccine Market: Focus on Product Type (Next-Generation Vaccine), Route of Administration, Disease Type, 22 Countries Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2028
Published: November 30, 2018 Content info: 278 Pages
Description

Global Vaccine Market to Reach $103.57 billion by 2028, Reports BIS Research

Vaccines protect people against serious and potentially deadly diseases. They produce immunity by injecting components and agents inside the body. They greatly reduce the risk of infection by working with the natural defense of the body to safely develop immunity to a disease. Vaccines are developed based on the type of information of the disease. They are also developed for the control of endemic situation and at the time of outbreak of the disease. Adjuvants are used in the vaccine to improve the efficiency and increase the immune response to the vaccine. Moreover, there are several safety and efficacy issues involved with the vaccines. In order to overcome these problems, next-generation vaccines are developed. Next-generation vaccines are currently in the product pipeline which includes, DNA vaccines, recombinant viral vector vaccines, and individualized vaccines. Individualized vaccines are developed based on the phenotype and genotype immune response of an individual.

The purpose of this study is to gain a holistic view of the global vaccine market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global vaccine market. The market has been segmented into "product", "disease", "route of administration", and "region". The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global vaccine market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global vaccine market. Moreover, the study includes detailed product mapping, market estimation and analysis of key trends in multiple geographical regions, growth of the vaccine market in each region for different cancer types, and the key strategies and developments by the prominent vaccine market stake holders.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global vaccine market?
  • What are the underlying structures resulting in the emerging trends within the vaccine industry?
  • What were the market values of the leading segments and sub-segments of the global vaccine market in 2017?
  • How will each segment of the global vaccine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period 2018-2028?
  • What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
  • What are the key vaccine type in vaccine market? What are the major benefits of each type?
  • How has the market been segmented on the basis of disease type? Which disease type is dominating the global vaccine market, and what is the reason behind its domination?
  • What are the market shares of each of the companies in the global vaccine market, and what are their contribution?
  • Who are the key manufacturers in the global vaccine market, and what are their contributions?
  • What is the scope of each vaccine type, route of administration, and disease type in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?
  • What are the key regulatory implications in developed and developing regions for vaccines?
  • What is the growth potential of vaccine in each region, including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?
  • Which vaccine type is having the most promising growth and in which disease type?

The key players who have been contributing significantly to the global vaccine market are Merck &Co., Inc., GlaxoSmithKline plc, Abbott Laboratories, Bavarian Nordic, Janssen Pharmaceutical NV, Pfizer, Inc., Sanofi Pasteur SA, and Seqirus (a CSL company), among others.

Executive Summary

There has been a continuous search in the medical world for better treatment and prevention approaches for various infectious and non-infectious diseases. This paved the way for the most awaited change in pediatric and adult vaccines. In the recent years, the impressive research on biologics for the development of DNA, recombinant, and cancer vaccines with better routes of administration, has opened new hopes to develop promising vaccines for different types of cancers, rare, and orphan diseases. Recent advancements in vaccine technologies especially in vaccine delivery platforms and ongoing clinical trials have resulted in the evolution of therapeutic as well as preventive vaccines.

Vaccines play a major role in developing immune responses by imitating an infection. Depending on the type of infection either caused by bacteria or virus, different approaches are used by the researchers to develop vaccines. Vaccines have been fruitful in the treatment and prevention of cancer and large pool of infectious diseases such as influenza, hepatitis, meningitis, rotavirus, human papilloma virus (HPV), and dengue, among others. Cancer, a global pandemic, is one of the leading causes of deaths worldwide. According to the research study conducted by the International Agency for Cancer Research, approximately 14.1 million new cancer cases were detected, and 8.2 million cancer deaths were reported in 2012. Moreover, considering the present prevalence rates, the number of cases detected are expected to grow over 21.7 million while the death counts are expected to reach 13 million. The rise in the count of cancer cases has been significantly increasing the global economic burden and was estimated at $1.16 trillion in 2010. The ongoing clinical trials for the development of cancer vaccines is aimed at enabling early diagnosis and treatment, thus consequentially aiding in combating cancer. Additionally, rising outbreaks of epidemic and zoonotic diseases in different parts of the globe has led to the development of preventive vaccines that helps occurrence and spread of these infections to a significant extent.

The purpose of this study is to gain a holistic view of the vaccine market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global vaccine market. The market has been segmented into "vaccine type", "route of administration", "disease type", and "region". The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

The global vaccine market is anticipated to reach $103.57 billion by 2028, witnessing a CAGR of 11.02% in the forecast period 2018-2028. Some of the factors such as growing prominence for the rising need for immunization coverage, substantial investments made in the field of research and development of novel vaccines and technologies, growing demand for cancer vaccines, and increasing incidence of infectious diseases and cancer coupled with rising geriatric population are acting as significant factors propelling the growth of the global vaccine market.

In terms of vaccine type, the global vaccine market is dominated by subunit and conjugate vaccine. Subunit and conjugate vaccines were developed when inactivated and killed vaccines failed to show significant results in the treatment and prevention of several diseases. Subunit vaccines can comprise from one to 20 antigens or more at times. Moreover, subunit vaccines use recombinant DNA technology as well for the antigen biomolecules from microbes. There are different types of subunit vaccines that are currently available in the market such as protein-based subunit vaccines, polysaccharide vaccines, and subunit conjugate vaccines. Furthermore, they are used in the treatment and prevention of large number of diseases such as influenza, hepatitis b, haemophilus influenza type B, pertussis, pneumococcal infections, and meningococcal diseases.

In terms of route of administration, the global vaccine market is dominated by intramuscular. In 2017, the market for intramuscular route of administration was valued $18.03 billion. Vaccines that are currently available in the market are majorly administered intramuscularly. Furthermore, this route of administration is effective for all age groups.

In terms of regional potential, North America is the leading contributor to the global vaccine market and contributed approximately 35% of the global market values in 2017. This can be attributed to high adoption rate of advanced technologies, increasing healthcare investments, presence of major manufacturers and increasing research and clinical trials by researchers and scientists for development of new vaccines across various universities in the region.

The key players who have been contributing significantly to the global vaccine market are Pfizer, Inc., Merck & Co., Inc., Emergent Biosolutions Inc., Abbott Laboratories, VBI Vaccines Inc., Madison Vaccines, Vical Inc., Inovio Pharmaceuticals Inc., GlaxoSmithKline plc, CSL Limited, AstraZeneca plc, LG Chem Ltd., Daiichi Sankyo Company, Limited, Sanofi S.A., Valneva SE, Bavarian Nordic, Sinovac Biotech Ltd., and Janssen Pharmaceutica NV, among others.

Table of Contents
Product Code: BH110A

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Different Types and Generation of Vaccines
    • 1.1.1 First-generation Vaccines
      • 1.1.1.1 Live Attenuated Vaccines
      • 1.1.1.2 Inactivated Vaccines (Killed)
    • 1.1.2 Second-generation Vaccines
      • 1.1.2.1 Subunit and Conjugate Vaccines
      • 1.1.2.2 Toxoid Vaccines
      • 1.1.2.3 Recombinant Vaccines
    • 1.1.3 Third-generation Vaccines
      • 1.1.3.1 DNA Vaccines
  • 1.2 Vaccines in a Historical Perspective
  • 1.3 Assumptions and Limitations for Market Size Calculations
  • 1.4 Global Vaccine Market Scenario

2 Market Dynamics

  • 2.1 Impact Analysis
  • 2.2 Market Drivers
    • 2.2.1 Increasing Outbreak of Epidemic Diseases
    • 2.2.2 Advancements in Vaccine Technologies and Emergence of Effective Vaccine Delivery System
    • 2.2.3 Increasing Global Focus on Immunization Program
    • 2.2.4 Use of Adjuvants in Vaccines
  • 2.3 Market Restraints
    • 2.3.1 Safety and Efficacy Related Issues
    • 2.3.2 Longer Timeline for Vaccine Production and High Cost Associated with Development of Vaccine
  • 2.4 Market Opportunities
    • 2.4.1 Development of Personalized Vaccines
    • 2.4.2 Implementation of Artificial Intelligence (AI) and Big Data Analytics to Improve Surveillance Capacity

3 Competitive Insights

  • 3.1 Key Strategies and Developments
    • 3.1.1 Product Launches and Enhancements
    • 3.1.2 Joint Ventures, Partnerships, and Collaborations
    • 3.1.3 Mergers and Acquisitions
    • 3.1.4 Business Expansions
    • 3.1.5 Others
  • 3.2 Market Share Analysis
  • 3.3 Industry Attractiveness
    • 3.3.1 Bargaining Power of Suppliers
    • 3.3.2 Bargaining Power of Buyer
    • 3.3.3 Threat of New Entrants
    • 3.3.4 Threat of Substitute Products
    • 3.3.5 Intensity of Competitive Rivalry

4 Industry Insights

  • 4.1 Introduction
  • 4.2 Regulatory Framework
    • 4.2.1 Legal Requirements and Framework for Vaccines in the U.S.
    • 4.2.2 Legal Requirements and Framework for Vaccines in the Europe
    • 4.2.3 Legal Requirements and Framework for Vaccines in the Asia-Pacific
  • 4.3 Regulatory Scenario
  • 4.4 Product Pipeline Analysis

5 Global Vaccine Market (by Route of Administration)

  • 5.1 Intramuscular (IM) Vaccine
  • 5.2 Subcutaneous Vaccine
  • 5.3 Oral Vaccine
  • 5.4 Intravenous (IV) Vaccine
  • 5.5 Other Vaccines

6 Global Vaccine Market (by Type)

  • 6.1 Subunit and Conjugate Vaccine
  • 6.2 Live Attenuated Vaccine
  • 6.3 Inactivated Vaccine
  • 6.4 Recombinant Vaccine
  • 6.5 Toxoid Vaccine
  • 6.6 Next-generation Vaccine

7 Global Vaccine Market (by Disease Type)

  • 7.1 Pneumococcal Disease
  • 7.2 Diphtheria, Tetanus, and Pertussis (DTP)
  • 7.3 Influenza
  • 7.4 Cancer
  • 7.5 Human Papilloma Virus (HPV)
  • 7.6 Meningococcal Disease
  • 7.7 Hepatitis
  • 7.8 Measles, Mumps, and Rubella (MMR)
  • 7.9 Rotavirus
  • 7.10 Varicella
  • 7.11 Other Diseases

8 Global Vaccine Market (by Region)

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 The U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 France
    • 8.3.3 The U.K.
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Switzerland
    • 8.3.7 Rest-of-Europe
  • 8.4 Asia-Pacific
    • 8.4.1 China
    • 8.4.2 India
    • 8.4.3 Japan
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest-of-APAC
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest-of-Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Gulf Cooperation Council (GCC)
    • 8.6.2 South Africa
    • 8.6.3 Rest-of-Middle East and Africa

9 Company Profiles

  • 9.1 Overview
  • 9.2 Abbott Laboratories
    • 9.2.1 Company Overview
    • 9.2.2 Role of Abbott Laboratories in Global Vaccine Market
    • 9.2.3 Financials
      • 9.2.3.1 Key Insights on Financial Health of Company
    • 9.2.4 SWOT Analysis
  • 9.3 AstraZeneca plc
    • 9.3.1 Company Overview
    • 9.3.2 Role of AstraZeneca plc in the Vaccine Market
    • 9.3.3 Financials
      • 9.3.3.1 Key Insights on Financial Health of Company
    • 9.3.4 SWOT Analysis
  • 9.4 BiondVax Pharmaceuticals Ltd.
    • 9.4.1 Company Overview
    • 9.4.2 Role of BiondVax Pharmaceuticals Ltd. In the Vaccine Market
    • 9.4.3 Financials
      • 9.4.3.1 Key Insights on the Financial Health of the Company
    • 9.4.4 SWOT Analysis
  • 9.5 Bavarian Nordic
    • 9.5.1 Company Overview
    • 9.5.2 Role of Bavarian Nordic in Global Vaccine Market
    • 9.5.3 Financials
      • 9.5.3.1 Key Insights on Financial Health of Company
    • 9.5.4 SWOT Analysis
  • 9.6 CSL Limited
    • 9.6.1 Company Overview
    • 9.6.2 Role of CSL Limited in the Vaccine Market
    • 9.6.3 Financials
      • 9.6.3.1 Key Insights on the Financial Health of the Company
    • 9.6.4 SWOT Analysis
  • 9.7 Daiichi Sankyo Company, Limited
    • 9.7.1 Company Overview
    • 9.7.2 Role of Daiichi Sankyo Company, Limited in Global Vaccine Market
    • 9.7.3 Financials
      • 9.7.3.1 Key Insights on Financial Health of Company
    • 9.7.4 SWOT Analysis
  • 9.8 Emergent BioSolutions Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Role of Emergent BioSolutions Inc. in the Vaccine Market
    • 9.8.3 Financials
      • 9.8.3.1 Key Insights on Financial Health of Company
    • 9.8.4 SWOT Analysis
  • 9.9 GlaxoSmithKline plc
    • 9.9.1 Company Overview
    • 9.9.2 Role of GlaxoSmithKline plc in Global Vaccine Market
    • 9.9.3 Financials
      • 9.9.3.1 Key Insights on Financial Health of Company
    • 9.9.4 SWOT Analysis
  • 9.10 Inovio Pharmaceuticals Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Role of Inovio pharmaceuticals Inc. in the Global vaccine market
    • 9.10.3 Financials
      • 9.10.3.1 Key Insights on the Financial Health of the Company
    • 9.10.4 SWOT Analysis
  • 9.11 Johnson & Johnson
    • 9.11.1 Company Overview
    • 9.11.2 Role of Johnson & Johnson in the Global Vaccine Market
    • 9.11.3 Financials
      • 9.11.3.1 Key Insights on the Financial Health of the Company
    • 9.11.4 SWOT Analysis
  • 9.12 Merck & Company Inc.
    • 9.12.1 Company Overview
    • 9.12.2 Role of Merck& Co., Inc. in the Global vaccine market
    • 9.12.3 Financials
      • 9.12.3.1 Key Insights on Financial Health of Company
    • 9.12.4 SWOT Analysis
  • 9.13 Madison Vaccines Incorporated
    • 9.13.1 Company Overview
    • 9.13.2 Role of Madison Vaccines Incorporated in the Global Vaccine Market
    • 9.13.3 SWOT Analysis
  • 9.14 Pfizer, Inc.
    • 9.14.1 Company Overview
    • 9.14.2 Role of Pfizer, Inc. Incorporated in the Global vaccine market
    • 9.14.3 Financials
      • 9.14.3.1 Key Insights on the Financial Health of the Company
    • 9.14.4 SWOT Analysis
  • 9.15 Sanofi S.A.
    • 9.15.1 Company Overview
    • 9.15.2 Role of Sanofi S.A. in the Vaccine Market
    • 9.15.3 Financials
      • 9.15.3.1 Key Insights on the Financial Health of the Company
    • 9.15.4 SWOT Analysis
  • 9.16 Sinovac Biotech Ltd.
    • 9.16.1 Company Overview
    • 9.16.2 Role of Sinovac Biotech Ltd. In the Global vaccine market
    • 9.16.3 Financials
      • 9.16.3.1 Key Insights on the Financial Health of the Company
    • 9.16.4 SWOT Analysis
  • 9.17 Valneva SE
    • 9.17.1 Company Overview
    • 9.17.2 Role of Valneva SE in the Global vaccine market
    • 9.17.3 Financials
      • 9.17.3.1 Key Insights on Financial Health of Company
    • 9.17.4 SWOT Analysis
  • 9.18 VBI Vaccine Inc.
    • 9.18.1 Company Overview
    • 9.18.2 Role of VBI Vaccine Inc. in the Global Vaccine Market
    • 9.18.3 Financials
      • 9.18.3.1 Key Insights on Financial Health of Company
    • 9.18.4 SWOT Analysis

10 Research Scope and Methodology

  • 10.1 Report Scope
  • 10.2 Global Vaccine Market: Research Methodology

List of Tables

  • Table 2.1 Impact Analysis
  • Table 2.2 Vaccination Coverage (by Vaccine and WHO Region) - Worldwide, 2016
  • Table 3.1 Number of Mergers and Acquisitions (by Each Company), January 2015-September 2018
  • Table 3.2 Number of Business Expansion (by Each Company), January 2015-September 2018
  • Table 4.1 The European Medicines Agency's Scientific Guidelines on Vaccines
  • Table 4.2 Regulatory Scenario Across the World
  • Table 7.1 Global Vaccine Market (by Disease Type), 2017-2028
  • Table 8.1 North America Vaccine Market (by Disease Type), 2017-2028
  • Table 8.2 Europe Vaccine Market (by Disease Type), 2017-2028 ($Billion)
  • Table 8.3 APAC Vaccine Market (by Disease Type), 2017-2028 ($Billion)
  • Table 8.4 Latin America Vaccine Market (by Disease Type), 2017-2028 ($Billion)
  • Table 8.5 Middle East and Africa Vaccine Market (by Disease Type), 2017-2028 ($Billion)

List of Figures

  • Figure 1 Global Vaccine Market Structure
  • Figure 2 Impact of Market Drivers and Market Restraints, 2017 and 2028
  • Figure 3 Global Vaccine Market Snapshot
  • Figure 4 Dominating Segments of Global Vaccine Market, 2017 and 2028
  • Figure 5 Global Vaccine Market (by Vaccine type), 2017 and 2028
  • Figure 6 Global Vaccine Market (by Route of Administration), 2017 and 2028
  • Figure 7 Global Vaccine Market (by Region), 2017 and 2028
  • Figure 8 Global Vaccine Market (by Region), 2017 and 2028
  • Figure 9 Market Statistics
  • Figure 10 Market Share Analysis: Global Vaccine Market, 2017
  • Figure 11 Opportunity Map Analysis of Next-generation Vaccines
  • Figure 1.1 Classification of Global Vaccine Market
  • Figure 1.2 Different Types and Generation of Vaccines
  • Figure 1.3 Components of a Vaccine
  • Figure 1.4 Evolution of Vaccines against Diseases
  • Figure 1.5 Global Vaccine Market, 2017-2028
  • Figure 2.1 Market Dynamics of Global Vaccine Market
  • Figure 3.1 Competitive Landscape, January 2015-September 2018
  • Figure 3.2 Share of Key Developments and Strategies, January 2015-September 2018
  • Figure 3.3 Product Launches Share (by Companies), January 2015- September 2018
  • Figure 3.4 Joint Ventures, Partnerships, and Collaborations Share (by Companies), January 2015-September 2018
  • Figure 3.5 Others Share (by Companies), January 2015-September 2018
  • Figure 3.6 Market Share Analysis: Global Vaccine Market, 2016 and 2017
  • Figure 3.7 Porter's Five Forces Analysis
  • Figure 3.8 Bargaining Power of Suppliers: Overall Impact, 2015-2028
  • Figure 3.9 Bargaining Power of Buyers: Overall Impact, 2015-2028
  • Figure 3.10 Threat of New Entrant: Overall Impact, 2015-2028
  • Figure 3.11 Threat of Substitute Products: Overall Impact, 2014-2028
  • Figure 3.12 Intensity of Competitive Rivalry: Overall Impact, 2015-2028
  • Figure 4.1 Industry Insights, January 2015-May 2018
  • Figure 4.2 Regulatory Pathway from Preclinical to the Marketing Authorization
  • Figure 4.3 Pipeline Analysis
  • Figure 4.4 Pipeline Analysis According to Clinical Trial Phases
  • Figure 5.1 Global Vaccine Market (by Route of Administration)
  • Figure 5.2 Global Vaccine Market (by Route of Administration), 2017-2028
  • Figure 5.3 Global Vaccine Market (by Intramuscular), 2017-2028
  • Figure 5.4 Global Vaccine Market (by Subcutaneous), 2017-2028
  • Figure 5.5 Global Vaccine Market (by Oral Vaccine), 2017-2028
  • Figure 5.6 Global Vaccine Market (by Intravenous vaccine), 2017-2028
  • Figure 5.7 Global Vaccine Market (by Others), 2017-2028
  • Figure 6.1 Global Vaccine Market (by Type)
  • Figure 6.2 Global Vaccine Market (by Type), 2017-2028
  • Figure 6.3 Global Vaccine Market (by Subunit and Conjugate), 2017-2028
  • Figure 6.4 Global Vaccine Market (by Live Attenuated), 2017-2028
  • Figure 6.5 Global Vaccine Market (by Inactivated), 2017-2028
  • Figure 6.6 Global Vaccine Market (by Recombinant), 2017-2028
  • Figure 6.7 Global Vaccine Market (by Toxoid), 2017-2028
  • Figure 6.8 Global Vaccine Market (by Next-Generation), 2021-2028
  • Figure 7.1 Global Vaccine Market (by Disease Type)
  • Figure 7.2 Global Vaccine Market (by Pneumococcal Disease), 2017-2028
  • Figure 7.3 Global Pneumococcal Disease Vaccine Market (by Region), 2017-2028
  • Figure 7.4 Global Vaccine Market (by DTP), 2017-2018
  • Figure 7.5 Global DTP Disease Vaccine Market (by Region), 2017-2028
  • Figure 7.6 Global Vaccine Market (by Influenza), 2017-2028
  • Figure 7.7 Global Influenza Vaccine Market (by Region), 2017-2028
  • Figure 7.8 Global Vaccine Market (by Cancer), 2017-2028
  • Figure 7.9 Global Cancer Vaccine Market (by Region), 2017-2028
  • Figure 7.10 Global Vaccine Market (by HPV), 2017-2028
  • Figure 7.11 Global HPV Vaccine Market (by Region), 2017-2028
  • Figure 7.12 Global Vaccine Market (by Meningococcal Disease), 2017-2028
  • Figure 7.13 Global Meningococcal Disease Vaccine Market (by Region), 2017-2028
  • Figure 7.14 Global Vaccine Market (by Hepatitis), 2017-2028
  • Figure 7.15 Global Hepatitis Disease Vaccine Market (by Region), 2017-2028
  • Figure 7.16 Global Vaccine Market (by MMR), 2017-2028
  • Figure 7.17 Global MMR Vaccine Market (by Region), 2017-2028
  • Figure 7.18 Global Vaccine Market (by Rotavirus), 2017-2028
  • Figure 7.19 Global Rotavirus Vaccine Market (by Region), 2017-2028
  • Figure 7.20 Global Vaccine Market (by Varicella), 2017-2028
  • Figure 7.21 Global Varicella Vaccine Market (by Region), 2017-2028
  • Figure 7.22 Global Vaccine Market (by Others), 2017-2028
  • Figure 8.1 Global Vaccine Market (by Region), 2017 and 2028
  • Figure 8.2 Global Vaccine Market (by Vaccine Market), 2017-2028
  • Figure 8.3 North America Vaccine Market, 2017-2028
  • Figure 8.4 North America: Market Dynamics
  • Figure 8.5 North America Vaccine Market (by Country), 2017-2028
  • Figure 8.6 North America Vaccine Market (by Vaccine Type), 2017-2028
  • Figure 8.7 North America Vaccine Market (by Route of Administration), 2017-2028
  • Figure 8.8 U.S. Vaccine Market, 2017-2028
  • Figure 8.9 Canada Vaccine Market, 2017-2028
  • Figure 8.10 Europe Vaccine Market, 2017-2028
  • Figure 8.11 Europe: Market Dynamics
  • Figure 8.12 Europe Vaccine Market (by Country), 2017-2028
  • Figure 8.13 Europe Vaccine Market (by Vaccine Type), 2017-2028
  • Figure 8.14 Europe Vaccine Market (by Route of Administration), 2017-2028
  • Figure 8.15 Germany Vaccine Market, 2017-2028
  • Figure 8.16 France Vaccine Market, 2017-2028
  • Figure 8.17 U.K. Vaccine Market, 2017-2028
  • Figure 8.18 Spain Vaccine Market, 2017-2028
  • Figure 8.19 Italy Vaccine Market, 2017-2028
  • Figure 8.20 Switzerland Vaccine Market, 2017-2028
  • Figure 8.21 Rest-of-Europe Vaccine Market, 2017-2028
  • Figure 8.22 APAC Vaccine Market, 2017-2028
  • Figure 8.23 APAC: Market Dynamics
  • Figure 8.24 APAC Vaccine Market (by Country), 2017-2028
  • Figure 8.25 APAC Vaccine Market (by Vaccine Type), 2017-2028
  • Figure 8.26 APAC Vaccine Market (by Route of Administration), 2017-2028
  • Figure 8.27 China Vaccine Market, 2017-2028
  • Figure 8.28 India Vaccine Market, 2017-2028
  • Figure 8.29 Japan Vaccine Market, 2017-2028
  • Figure 8.30 Australia Vaccine Market, 2017-2028
  • Figure 8.31 South Korea Vaccine Market, 2017-2028
  • Figure 8.32 Rest-of-APAC Vaccine Market, 2017-2028
  • Figure 8.33 Latin America Vaccine Market, 2017-2028
  • Figure 8.34 Latin America: Market Dynamics
  • Figure 8.35 Latin America Vaccine Market (by Country), 2017-2028
  • Figure 8.36 Latin America Vaccine Market (by Vaccine Type), 2017-2028
  • Figure 8.37 Latin America Vaccine Market (by Route of Administration), 2017-2028
  • Figure 8.38 Brazil Vaccine Market, 2017-2028
  • Figure 8.39 Mexico Vaccine Market, 2017-2028
  • Figure 8.40 Rest-of-Latin America Vaccine Market, 2017-2028
  • Figure 8.41 Middle East and Africa Vaccine Market, 2017-2028
  • Figure 8.42 Middle East and Africa: Market Dynamics
  • Figure 8.43 Middle East and Africa Vaccine Market (by Country), 2017-2028
  • Figure 8.44 Middle East and Africa Vaccine Market (by Vaccine Type), 2017-2028
  • Figure 8.45 Middle East and Africa Vaccine Market (by Route of Administration), 2017-2028
  • Figure 8.46 GCC Vaccine Market, 2017-2028
  • Figure 8.47 South Africa Vaccine Market, 2017-2028
  • Figure 8.48 Rest-of- Middle East and Africa Vaccine Market, 2017-2028
  • Figure 9.1 Share of Key Company Profiled
  • Figure 9.2 Abbott India Ltd. (Subsidiary of Abbott Laboratories): Product Offerings for Global Vaccine Market
  • Figure 9.3 Abbott Laboratories: Overall Financials, 2015-2017
  • Figure 9.4 Abbott Laboratories: Revenue (by Business Segment), 2015-2017
  • Figure 9.5 Abbott Laboratories: Revenue (by Region), 2015-2017
  • Figure 9.6 Abbott Laboratories: R&D Expense, 2015-2017
  • Figure 9.7 Abbott Laboratories: Revenue Forecast, 2015-2020
  • Figure 9.8 Abbott Laboratories: SWOT Analysis
  • Figure 9.9 AstraZeneca plc: Product Offerings for Global Vaccine Market
  • Figure 9.10 AstraZeneca plc: Overall Financials, 2015-2017
  • Figure 9.11 AstraZeneca plc: Revenue (by Region), 2015-2017
  • Figure 9.12 AstraZeneca plc: R&D Expense, 2015-2017
  • Figure 9.13 AstraZeneca PLC: SWOT Analysis
  • Figure 9.14 BiondVax Pharmaceuticals Ltd.: Overall Financials, 2015-2017
  • Figure 9.15 BiondVax Pharmaceuticals Ltd.: R&D Expense, 2015-2017
  • Figure 9.16 BiondVax Pharmaceuticals Ltd.: SWOT Analysis
  • Figure 9.17 Bavarian Nordic: Overall Financials, 2015-2017
  • Figure 9.18 Bavarian Nordic: Revenue (by Region), 2015-2017
  • Figure 9.19 Bavarian Nordic: R&D Expense, 2015-2017
  • Figure 9.20 Bavarian Nordic: Revenue Forecast, 2015-2020
  • Figure 9.21 Bavarian Nordic: SWOT Analysis
  • Figure 9.22 CSL Limited: Product Offerings for Global Vaccine Market
  • Figure 9.23 CSL Limited: Overall Financials, 2015-2017
  • Figure 9.24 CSL Limited: Revenue (by Business Segment), 2015-2017
  • Figure 9.25 CSL Limited: Revenue (by Region), 2015-2017
  • Figure 9.26 CSL Limited: R&D Expense, 2015-2017
  • Figure 9.27 CSL Limited: Revenue Forecast, 2015-2020
  • Figure 9.28 CSL Limited: SWOT Analysis
  • Figure 9.29 Daiichi Sankyo Company, Limited: Product Offerings for Global Vaccine Market
  • Figure 9.30 Daiichi Sankyo Company, Limited: Overall Financials, 2015-2017
  • Figure 9.31 Daiichi Sankyo Company, Limited: Revenue (by Business Segment), 2015-2017
  • Figure 9.32 Daiichi Sankyo Company, Limited: Revenue (by Region), 2015-2017
  • Figure 9.33 Daiichi Sankyo Company, Limited: R&D Expense, 2015-2017
  • Figure 9.34 Daiichi Sankyo Company, Limited: Revenue Forecast, 2015-2020
  • Figure 9.35 Daiichi Sankyo Company, Limited: SWOT Analysis
  • Figure 9.36 Emergent BioSolutions Inc.: Product Offerings for Global Vaccine Market
  • Figure 9.37 Emergent BioSolutions Inc.: Overall Financials, 2015-2017
  • Figure 9.38 Emergent BioSolutions Inc.: Revenue (by Region), 2015-2017
  • Figure 9.39 Emergent BioSolutions Inc.: R&D Expense, 2015-2017
  • Figure 9.40 Emergent BioSolution Inc.: Revenue Forecast, 2015-2020
  • Figure 9.41 Emergent BioSolutions Inc.: SWOT Analysis
  • Figure 9.42 GlaxoSmithKline plc: Product Offerings for Global Vaccine Market
  • Figure 9.43 GlaxoSmithKline plc: Overall Financials, 2015-2017
  • Figure 9.44 GlaxoSmithKline plc: Revenue (by Business Segment), 2015-2017
  • Figure 9.45 GlaxoSmithKline plc: Revenue (by Region), 2015-2017
  • Figure 9.46 GlaxoSmithKline plc: R&D Expense, 2015-2017
  • Figure 9.47 GlaxoSmithKline plc: Revenue Forecast, 2015-2020
  • Figure 9.48 GlaxoSmithKline plc: SWOT Analysis
  • Figure 9.49 Product Offerings
  • Figure 9.50 Inovio Pharmaceuticals Inc.: Overall Financials, 2015-2017
  • Figure 9.51 Inovio Pharmaceuticals Inc..: R&D Expense, 2015-2017
  • Figure 9.52 Inovio pharmaceuticals Inc.: Revenue Forecast, 2015-2020
  • Figure 9.53 Inovio Pharmaceutical Inc.: SWOT Analysis
  • Figure 9.54 Johnson & Johnson: Product Offerings for Global Vaccine Market
  • Figure 9.55 Johnson & Johnson: Overall Financials, 2015-2017
  • Figure 9.56 Johnson & Johnson: Revenue (by Business Segment), 2015-2017
  • Figure 9.57 Johnson & Johnson: Revenue (by Region), 2015-2017
  • Figure 9.58 Johnson & Johnson: R&D Expense, 2015-2017
  • Figure 9.59 Johnson & Johnson: Revenue Forecast, 2015-2020
  • Figure 9.60 Johnson & Johnson: SWOT Analysis
  • Figure 9.61 Merck & Co. Inc.: Product Offerings for Global Vaccine Market
  • Figure 9.62 Merck & Co: Overall Financials, 2015-2017
  • Figure 9.63 Merck & Co. Inc..: Revenue (by Business Segment), 2015-2017
  • Figure 9.64 Merck & Co. Inc..: Revenue (by Region), 2015-2017
  • Figure 9.65 Merck & Co. Inc..: R&D Expense, 2015-2017
  • Figure 9.66 Merck & Co. Inc..: Revenue Forecast, 2015-2020
  • Figure 9.67 Merck & Co. Inc.: SWOT Analysis
  • Figure 9.68 Madison Vaccines Incorporated: SWOT Analysis
  • Figure 9.69 Pfizer, Inc.: Product Offerings for Global Vaccine Market
  • Figure 9.70 Pfizer, Inc.: Overall Financials, 2015-2017
  • Figure 9.71 Pfizer, Inc.: Revenue (by Business Segment) 2015-2017
  • Figure 9.72 Pfizer, Inc.: Revenue (by Region) 2015- 2017
  • Figure 9.73 Pfizer, Inc.: R&D Expense, 2015-2017
  • Figure 9.74 Pfizer, Inc.: Revenue Forecast, 2015-2020
  • Figure 9.75 Pfizer, Inc.: SWOT Analysis
  • Figure 9.76 Sanofi S.A.: Product Offerings for Global Vaccine Market
  • Figure 9.77 Pipeline Products
  • Figure 9.78 Sanofi S.A.: Overall Financials, 2015-2017
  • Figure 9.79 Sanofi S.A..: Revenue (by Business Segment), 2015-2017
  • Figure 9.80 Sanofi S.A.: Revenue (by Region), 2015-2017
  • Figure 9.81 Sanofi S.A.: R&D Expense, 2015-2017
  • Figure 9.82 Sanofi S.A..: Revenue Forecast, 2015-2020
  • Figure 9.83 Sanofi S.A..: SWOT Analysis
  • Figure 9.84 Sinovac Biotech Ltd.: Product Offerings for Global Vaccine Market
  • Figure 9.85 Sinovac Biotech Ltd..: Overall Financials, 2015-2017
  • Figure 9.86 Sinovac: Revenue (by Region), 2015-2017
  • Figure 9.87 Sinovac Biotech Ltd.: R&D Expense, 2015-2017
  • Figure 9.88 Sinovac Biotech Ltd.: Revenue Forecast, 2015-2020
  • Figure 9.89 Sinovac Biotech Ltd.: SWOT Analysis
  • Figure 9.90 Valneva SE: Product Offerings for Global Vaccine Market
  • Figure 9.91 Valneva SE.: Overall Financials, 2015-2017
  • Figure 9.92 Valneva SE: Revenue (by Business Segment), 2015-2017
  • Figure 9.93 Valneva SE: Revenue (by Region), 2015 & 2017
  • Figure 9.94 Valneva SE: R&D Expense, 2015-2017
  • Figure 9.95 Valneva SE: Revenue Forecast, 2015-2020
  • Figure 9.96 Valneva SE.: SWOT Analysis
  • Figure 9.97 VBI Vaccine Inc.: Product Offerings for Global Vaccine Market
  • Figure 9.98 VBI Vaccine Inc.: Overall Financials, 2015-2017
  • Figure 9.99 VBI Vaccine Inc. Revenue (by Region) 2015-2017
  • Figure 9.10 0 VBI Vaccine Inc.: R&D Expense, 2015-2017
  • Figure 9.10 1 VBI Vaccine Inc.: SWOT Analysis
  • Figure 10.1 Global Vaccine Market: Market Segmentation
  • Figure 10.2 Global Vaccine Market Segmentation
  • Figure 10.3 Primary Research
  • Figure 10.4 Secondary Research
  • Figure 10.5 Data Triangulation
  • Figure 10.6 Top-down Approach (Segment-wise Analysis)
  • Figure 10.7 Bottom-up Approach (Segment-wise Analysis)
  • Figure 10.8 Assumptions and Limitations
  • Figure 10.9 Considered Factors for Data Prediction and Modelling
Back to Top